✦ LIBER ✦

A randomized Phase II trial of two dosage levels of letrozole as third-line hormonal therapy for women with metastatic breast carcinoma

✍ Scribed by James N. Ingle; Patricia A. Johnson; Vera J. Suman; James B. Gerstner; James A. Mailliard; John K. Camoriano; Dean H. Gesme Jr.; Charles L. Loprinzi; Alan K. Hatfield; Lynn C. Hartmann

Publisher: John Wiley and Sons
Year: 1997
Tongue: English
Weight: 88 KB
Volume: 80
Category: Article
ISSN: 0008-543X
DOI: 10.1002/(sici)1097-0142(19970715)80:2<218::aid-cncr8>3.0.co;2-p

No coin nor oath required. For personal study only.

✦ Synopsis

letrozole dosage levels, 0.5 mg and 2.5 mg per day, was performed. Eligibility requirements included failure on two prior hormonal therapies and measurable

📜 SIMILAR VOLUMES

A phase II study of paclitaxel plus carb

A phase II study of paclitaxel plus carboplatin as first-line chemotherapy for women with metastatic breast carcinoma

✍ Edith A. Perez; David W. Hillman; Philip J. Stella; James E. Krook; Lynn C. Hart 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 96 KB 👁 1 views

## BACKGROUND. This Phase II multicenter study evaluated the efficacy and toxicity of paclitaxel (200 mg/m 2 by 3-hour infusion) with carboplatin (area under the curve 6 mg/mL per minute) administered every 3 weeks as first-line therapy for women with metastatic breast carcinoma. ## METHODS. Eligi